These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8067751)

  • 1. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime.
    Imtiaz U; Manavathu EK; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1994 May; 38(5):1134-9. PubMed ID: 8067751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of a unique ceftazidime-hydrolysing beta-lactamase, TEM-E2.
    Payne DJ; Marriott MS; Amyes SG
    J Med Microbiol; 1990 Jun; 32(2):131-4. PubMed ID: 2192063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective ceftazidime resistance in Escherichia coli: association with changes in outer membrane protein.
    Bakken JS; Sanders CC; Thomson KS
    J Infect Dis; 1987 Jun; 155(6):1220-5. PubMed ID: 3553348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
    Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
    Brown RP; Aplin RT; Schofield CJ
    Biochemistry; 1996 Sep; 35(38):12421-32. PubMed ID: 8823177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
    Stapleton PD; Shannon KP; French GL
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
    Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.
    Zhou XY; Bordon F; Sirot D; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1994 May; 38(5):1085-9. PubMed ID: 8067742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
    Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
    J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.
    Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.
    Schroeder WA; Locke TR; Jensen SE
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3568-73. PubMed ID: 12384366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotaxime and ceftazidime-resistant Escherichia coli isolate producing TEM-15 beta-lactamase from a Tunisian hospital.
    Chouchani C; Ben-Achour N; M'charek A; Belhadj O
    C R Biol; 2007 Aug; 330(8):565-70. PubMed ID: 17637436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
    Sulton D; Pagan-Rodriguez D; Zhou X; Liu Y; Hujer AM; Bethel CR; Helfand MS; Thomson JM; Anderson VE; Buynak JD; Ng LM; Bonomo RA
    J Biol Chem; 2005 Oct; 280(42):35528-36. PubMed ID: 15987690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the omega-loop confers ceftazidime resistance.
    Kurokawa H; Shibata N; Doi Y; Shibayama K; Kamachi K; Yagi T; Arakawa Y
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2981-3. PubMed ID: 12937007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli.
    Paul GC; Gerbaud G; Bure A; Philippon AM; Pangon B; Courvalin P
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1958-63. PubMed ID: 2692515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.
    Vakulenko S; Golemi D
    Antimicrob Agents Chemother; 2002 Mar; 46(3):646-53. PubMed ID: 11850243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
    Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.